Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson’s Disease (PD), representing the only drug to address both movement and non-movement symptoms of PDArmesocarb is the active...